This invention provides a pharmaceutical composition comprising a lipase inhibitor a lipophilic oil absorbent selected from the group consisting of hydrogenated castor oil, hydrogenated vegetable oil, glyceryl behenate, glyceryl palmitostearate and a mixture thereof and a pharmaceutically acceptable additive, an oral formulation of a lipase inhibitor prepared there from and a method for preparing said formulation. The formulation of the present invention can minimize side effects such as oily spotting, fatty/oily stool, abdominal distension and flatus, and thus it can be advantageously used for preventing or treating obesity and hyperlipaemia.
